Rare Daily Staff
QurAlis said the U.S. Food and Drug Administration has cleared its application to begin U.S. clinical testing of QRL-201, an experimental treatment for the rare neurodegenerative disease amyotrophic lateral sclerosis, as the company reported early trial results suggesting the drug may slow patients’ functional decline.
The company plans to launch a pivotal trial, called CONQUR, in the first half of 2027. The study would seek to establish evidence needed to support a potential application for approval.
The company also reported final results from the dose-range-finding portion of its phase 1/2 ANQUR trial. That portion enrolled 52 participants and compared two doses of QRL-201—3 milligrams and 10 milligrams—with placebo.
At day 253, participants receiving the 10-milligram dose had a 50 percent slower rate of functional decline than those receiving placebo, as measured by the ALS Functional Rating Scale–Revised, or ALSFRS-R, the company said. The difference was statistically significant. Participants receiving the lower dose also showed slower decline, although the release did not report the size or statistical significance of that functional benefit.
The finding represents a reduction in the rate of worsening. QurAlis did not provide the underlying changes in functional scores, the number of participants in each treatment group, or confidence intervals in its announcement, limiting assessment of the result’s magnitude and precision.
QRL-201 is an antisense oligonucleotide designed to restore production of STATHMIN-2, a protein that helps maintain nerve fibers and their connections to muscles. The company says levels of the protein are reduced in most people with ALS.
The reported efficacy results involved people with sporadic ALS, meaning cases without an identified family history of the disease. The broader ANQUR study was designed to include people with sporadic ALS and ALS associated with changes in the C9orf72 gene.
“The findings from the ANQUR clinical trial are promising and justify additional clinical research into QRL-201 as a potential treatment option for individuals with sporadic ALS,” said Merit Cudkowicz, director of the Sean M. Healey & AMG Center for ALS and a member of QurAlis’ clinical advisory board.
QurAlis also reported reductions in neurofilaments, proteins measured as indicators of nerve-fiber damage. In the 3-milligram group, levels of phosphorylated neurofilament heavy in cerebrospinal fluid fell 46 percent from baseline at day 197, the last time point measured. That change was statistically significant.
Blood levels of another marker, neurofilament light, fell 18 percent from baseline in the 3-milligram group at day 337 and 36 percent in the 10-milligram group at day 421. Both changes were statistically significant.
However, the reported 31 percent reduction in blood neurofilament light compared with placebo in the lower-dose group did not meet the conventional threshold for statistical significance. The distinction matters because a change from a patient’s starting level is a different comparison from a treatment’s effect relative to placebo.
The company described QRL-201 as generally well tolerated, with most adverse events mild or moderate. It reported no serious adverse events during the dose-range-finding portion of the trial.
ANQUR has now moved entirely into an open-label extension, in which 41 participants are receiving the 3-milligram dose in Canada, the United Kingdom, and the European Union. QurAlis said it expects to disclose more details about the planned pivotal trial in early 2027.
Related
Every Cure and OpenEvidence Team Up to Find New Uses for Existing Drugs
Rare Daily Staff Nonprofit biotech Every Cure is partnering with medical artificial intelligence company OpenEvidence to develop […]
Read moreFDA Approves First Treatment for Rare Autoimmune Kidney Disease
Rare Daily Staff The U.S. Food and Drug Administration has approved Genentech’s Gazyva for primary membranous nephropathy, […]
Read moreSanthera Signs Deal to Expand Access to DMD Treatment in Latin America and the Caribbean
Rare Daily Staff Santhera Pharmaceuticals said it signed an exclusive distribution agreement with SteinCares for its Duchenne […]
Read moreThe Promise of a Peptide to Break the Cycle of Blood Draws in Polycythemia Vera
People with polycythemia vera can face a recurring cycle of excess red blood cell production, blood withdrawals, […]
Read moreBeam Reports Positive Pivotal Results for Sickle Cell Gene-Editing Therapy
Rare Daily Staff Beam Therapeutics said Tuesday that its experimental sickle cell disease therapy, built on a […]
Read moreBioNTech Buys Scholar Rock’s Priority Review Voucher for $205 Million
Rare Daily Staff BioNTech, the German drugmaker best known for the COVID-19 vaccine it developed with Pfizer, […]
Read moreMirum Reports Positive Late-Stage Data for Hep D
Rare Daily Staff Mirum Pharmaceuticals said its experimental therapy brelovitug met the main goal of a phase […]
Read moreAbeona Acquires Experimental Swallowing-Disorder Drug
Rare Daily Staff Abeona Therapeutics has acquired an experimental once-daily treatment for eosinophilic esophagitis, a chronic inflammatory […]
Read moreAvanzanite Licenses European Rights to Blood Cancer Cell Therapy Zemcelpro
Rare Daily Staff Avanzanite Bioscience has secured exclusive rights to commercialize the stem cell therapy Zemcelpro across […]
Read more
